Literature DB >> 25708551

Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting.

G Catho1, S Couraud2, S Grard3, A Bouaziz3, A Sénéchal3, F Valour3, T Perpoint3, E Braun3, F Biron3, T Ferry4, C Chidiac3, N Freymond2, E Perrot2, P-J Souquet2, J-M Maury5, F Tronc5, N Veziris6, G Lina7, O Dumitrescu7, F Ader8.   

Abstract

Multidrug-resistant (MDR) tuberculosis (TB) is an emerging concern in communities with a low TB prevalence and a high standard of public health. Twenty-three consecutive adult MDR TB patients who were treated at our institution between 2007 and 2013 were reviewed for demographic characteristics and anti-TB treatment management, which included surgical procedures and long-term patient follow-up. This report of our experience emphasizes the need for an individualized approach as MDR TB brings mycobacterial disease management to a higher level of expertise, and for a balance to be found between international current guidelines and patient-tailored treatment strategies.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bedaquiline; MDR TB surgery; Mycobacterium tuberculosis; multidrug-resistant tuberculosis; negative-pressure ventilation room

Mesh:

Substances:

Year:  2015        PMID: 25708551     DOI: 10.1016/j.cmi.2014.12.022

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

1.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

2.  Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Authors:  Soazic Grard; Gaud Catho; Florent Valour; Anissa Bouaziz; Thomas Perpoint; Evelyne Braun; François Biron; Patrick Miailhes; Tristan Ferry; Christian Chidiac; Pierre-Jean Souquet; Sébastien Couraud; Gérard Lina; Sylvain Goutelle; Nicolas Veziris; Oana Dumitrescu; Florence Ader
Journal:  Open Forum Infect Dis       Date:  2015-12-22       Impact factor: 3.835

3.  First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB.

Authors:  Joseph M Lewis; Paul Hine; Jenny Walker; Saye H Khoo; Miriam Taegtmeyer; S Bertel Squire; Derek J Sloan
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.